The most significant aspect of reduction of hospital stay, as Dr. Javitt pointed out in the Dr. Yo interview, was that this was the "bar" that was set for Remidisivar's EUA. In addition, at the time of Remdisivar's EUA their reduction in number of days data was "trending toward significant significance". Not only did Zyesami show a greater reduction in length of stay vs a placebo than Remidisivar -- it did so with a statistically significant high degree of confidence (1 in 2000 it occurred to "chance") that Remidisivar was unable to show.
So, Zyesami showed better results with a better degree of confidence than the current SOC drug that has already been granted an EUA. We also showed no safety concerns. To grant an EUA; a drug has to be shown to be safe and "may" be effective. The FDA set the "bar" for therapeutic approvals, we shared with them data that showed we surpassed the bar. We shared this additional data with the FDA for the already pending EUA application because the FDA asked for more data. We gave them exactly what they asked for and it was very compelling data.
Letting the science and data outcomes speak for themselves is the approach RLF & NRX has taken, I applaud them for that. I for one do not need hyped up interviews, I rely on the underlying facts. While others might disagree and have a real fit, I am glad they did not do a "superbeau halftime TV ad". Once/If a EUA is granted, the PR and media will create more interest than the company could possibly generate on its own even. I am waiting for more data analysis to be released, the good news is that more data analysis is coming soon.
Best,
JB
News 
Market Data 
Discover 
